Ahmed Elkhanany Profile | University of ...

Dr. Ahmed Elkhanany

Claim this profile

University of Alabama at Birmingham Cancer Center

Studies Breast Cancer
Studies Breast cancer
11 reported clinical trials
26 drugs studied

Area of expertise

1Breast Cancer
Ahmed Elkhanany has run 10 trials for Breast Cancer. Some of their research focus areas include:
Stage IV
ER positive
Stage III
2Breast Cancer
Ahmed Elkhanany has run 6 trials for Breast cancer. Some of their research focus areas include:
Stage IV
HER2 negative
HER2 positive

Affiliated Hospitals

Image of trial facility.
University Of Alabama At Birmingham Cancer Center
Image of trial facility.
University Of Alabama At Birmingham

Clinical Trials Ahmed Elkhanany is currently running

Image of trial facility.

Lasofoxifene and Abemaciclib vs Fulvestrant and Abemaciclib

for Breast Cancer

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.
Recruiting2 awards Phase 312 criteria
Image of trial facility.

Dato-DXd + T-DXd

for Breast Cancer

The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab deruxtecan) to learn whether the treatment works in treating HER2-negative (HER2-low or HER2-0) metastatic breast cancer. The names of the study drugs involved in this study are: * Datopotamab deruxtecan (a type of antibody drug conjugate) * Trastuzumab deruxtecan (a type of antibody drug conjugate)
Recruiting1 award Phase 27 criteria

More about Ahmed Elkhanany

Clinical Trial Related2 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Ahmed Elkhanany has experience with
  • Avelumab
  • Trastuzumab
  • Paclitaxel
  • Abemaciclib
  • Fulvestrant
  • Estradiol

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Ahmed Elkhanany specialize in?
Is Ahmed Elkhanany currently recruiting for clinical trials?
Are there any treatments that Ahmed Elkhanany has studied deeply?
What is the best way to schedule an appointment with Ahmed Elkhanany?
What is the office address of Ahmed Elkhanany?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security